ZyVersa Therapeutics, Inc. (ZVSA) Dividend History

Company News

• ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

  ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported progress in its Phase 2a trial for Cholesterol Efflux Mediator™ VAR 200 in diabetic kidney disease and plans for its Inflammasome ASC Inhibitor IC 100 in obesity with metabolic complications. The company raised $0.8 million from warrant exercises and expects its current cash to fund operations on a month-to-month basis.

  GlobeNewswire Inc.
• ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

  ZyVersa is on track to achieve key development milestones over the next 3 quarters.

  GlobeNewswire Inc.
• ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

  To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

  GlobeNewswire Inc.
• ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

  NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.

  GlobeNewswire Inc.
• ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

  Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.

  GlobeNewswire Inc.